IP Library Granted Patent US 7,105,673
Granted Patent B2
US 7,105,673 · App. 10/282,325 · Granted Sep 12, 2006

Cardioprotective phosphonates and malonates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,105,673
App. No.
10/282,325
Granted
Sep 12, 2006
Kind
B2
Abstract

The present invention provides for pyridoxine phosphonate analogues such as, for example, ((2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl)alkylphosphonates, and (2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl)azaalkylphosphonates) and to pyridoxine malonate analogues, such as, for example, ((2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridylmethyl)malonates), pharmaceutical compositions, and methods for treatment of cardiovascular and related diseases, and diabetes mellitus and related diseases.

Claims (21)

1. A compound of the formula III

in which

R 1 is hydrogen or alkyl;

R 2 is CHO, —CH 2 OH, —CH 3 or CO 2 R 8 in which R 8 is hydrogen, alkyl, or aryl; or

R 2 is —CH 2—0 -alkyl- in which alkyl is covalently bonded to the oxygen at the 3-position instead of R 1 ;

R 3 is hydrogen and R 4 is hydroxy, halo, alkoxy or alkylcarbonyloxy; or

R 3 and R 4 can be taken together to form ═O;

R 5 and R 6 are hydrogen; or

R 5 and R 6 are halo; and

R 7 is hydrogen, alkyl, aryl, aralkyl, or CO 2 R 8 in which R 8 is hydrogen, alkyl, aryl, or aralkyl;

or a pharmaceutically acceptable acid addition salt thereof.

2. A compound according to claim 1 , wherein R 1 is hydrogen.

3. A compound according to claim 1 , wherein R 2 is —CH 2 O or —CH 2— O-alkyl- in which alkyl is covalently bonded to the oxygen at the 3-position instead of R 1 .

4. A compound according to claim 1 , wherein R 4 is —OH or CH 3 C(O)O—.

5. A compound according to claim 1 , wherein R 3 and R 4 taken together form ═O.

6. A compound according to claim 1 , wherein R 5 and R 6 are F.

7. A compound according to claim 1 , wherein R 7 is alkyl.

8. A compound according to claim 7 , wherein R 7 is ethyl.

9. A compound according to claim 1 selected from

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 1 .

11. A pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is in a form suitable for enteral or parenteral administration.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Dec 5, 2008
From: GE CANADA ASSET FINANCE HOLDING COMPANY, SUCCESSOR AS AGENT TO MERRILL LYNCH CAPITAL CANADA INC.
To: MEDICURE INTERNATIONAL INC.
Reel/Frame 021924/0586 →
SECURITY AGREEMENT Recorded Aug 15, 2006
From: MEDICURE INTERNATIONAL INC.
To: MERRILL LYNCH CAPITAL CANADA INC.
Reel/Frame 018109/0041 →